Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.

Fozza C, La Nasa G, Caocci G.

Crit Rev Oncol Hematol. 2019 Jul 26;142:51-57. doi: 10.1016/j.critrevonc.2019.07.018. [Epub ahead of print] Review.

PMID:
31376677
2.

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Crobu V, Caocci G, La Nasa G, Saderi L, Sotgiu G, Fozza C.

Mediterr J Hematol Infect Dis. 2019 May 1;11(1):e2019032. doi: 10.4084/MJHID.2019.032. eCollection 2019. No abstract available.

3.

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F.

Ann Hematol. 2019 Aug;98(8):1933-1936. doi: 10.1007/s00277-019-03727-6. Epub 2019 Jun 14.

PMID:
31201513
4.

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.

Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1.

PMID:
31044260
5.

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M.

Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

PMID:
31029498
6.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Mar 20. doi: 10.1002/hon.2606. [Epub ahead of print]

PMID:
30892724
7.

Acute basophilic leukemia with U2AF1 mutation.

Carruale A, Muntone G, Rojas R, Bonfigli S, Virdis P, Longu F, Valdes G, Piras G, Uras A, Palmas A, Caocci G, La Nasa G, Fozza C.

Blood Cells Mol Dis. 2019 May;76:63-65. doi: 10.1016/j.bcmd.2019.02.002. Epub 2019 Feb 22. No abstract available.

PMID:
30827760
8.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

9.

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.

Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M.

Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3.

PMID:
30714299
10.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

11.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

12.

Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis.

Caocci G, Ghiani S, Mocci C, La Nasa G.

Acta Haematol. 2018;139(3):164-165. doi: 10.1159/000487582. Epub 2018 Mar 29. No abstract available.

13.

Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.

Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, Castagnetti F, Palumbo GA, Iurlo A, Landi F.

Ann Hematol. 2018 May;97(5):745-754. doi: 10.1007/s00277-018-3258-0. Epub 2018 Feb 22. Review.

PMID:
29468276
14.

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation.

Caocci G, Atzeni S, Usai M, La Nasa G.

Leuk Res Rep. 2017 Dec 27;9:14-15. doi: 10.1016/j.lrr.2017.12.002. eCollection 2018.

15.

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

16.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

17.

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group.

Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.

18.

How We Manage Invasive Fungal Disease in Acute Myeloid Leukemia Patients with Glucose 6 Dehydrogenase Deficiency.

Sanna M, Caocci G, La Nasa G.

Mediterr J Hematol Infect Dis. 2017 Aug 14;9(1):e2017047. doi: 10.4084/MJHID.2017.047. eCollection 2017.

19.

Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.

Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, Caria R, Pilia MP, Origa R, Moi P, La Nasa G.

Am J Hematol. 2017 Dec;92(12):1303-1310. doi: 10.1002/ajh.24898. Epub 2017 Sep 25.

20.

HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia.

Caocci G, Greco M, Arras M, Cusano R, Orrù S, Martino B, Abruzzese E, Galimberti S, Mulas O, Trucas M, Littera R, Lai S, Carcassi C, La Nasa G.

Leuk Res. 2017 Oct;61:1-5. doi: 10.1016/j.leukres.2017.08.005. Epub 2017 Aug 18.

PMID:
28841441
21.

Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.

Martino B, Mammì C, Labate C, Rodi S, Ielo D, Priolo M, Postorino M, Tripepi G, Ronco F, Laganà C, Musolino C, Greco M, La Nasa G, Caocci G.

Exp Hematol. 2017 Nov;55:71-75. doi: 10.1016/j.exphem.2017.07.007. Epub 2017 Jul 28.

PMID:
28757432
22.

KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.

Littera R, Piredda G, Argiolas D, Lai S, Congeddu E, Ragatzu P, Melis M, Carta E, Michittu MB, Valentini D, Cappai L, Porcella R, Alba F, Serra M, Loi V, Maddi R, Orrù S, La Nasa G, Caocci G, Cusano R, Arras M, Frongia M, Pani A, Carcassi C.

PLoS One. 2017 Jul 7;12(7):e0180831. doi: 10.1371/journal.pone.0180831. eCollection 2017.

23.

Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.

Sanna M, Caocci G, Orrù F, Ledda A, Vacca A, Piras E, Fozza C, Deias P, Tidore G, Dore F, La Nasa G.

J Clin Pharm Ther. 2017 Dec;42(6):733-737. doi: 10.1111/jcpt.12571. Epub 2017 Jun 8.

PMID:
28597476
24.

Bone Marrow Homing and Engraftment Defects of Human Hematopoietic Stem and Progenitor Cells.

Caocci G, Greco M, La Nasa G.

Mediterr J Hematol Infect Dis. 2017 Apr 19;9(1):e2017032. doi: 10.4084/MJHID.2017.032. eCollection 2017. Review.

25.

Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.

Sanna M, Caocci G, Ledda A, Orrù F, Fozza C, Deias P, Tidore G, Dore F, La Nasa G.

Leuk Lymphoma. 2017 Nov;58(11):2558-2564. doi: 10.1080/10428194.2017.1312666. Epub 2017 Apr 12.

PMID:
28402154
26.

What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught us about Transplant Immunogenetics.

La Nasa G, Vacca A, Littera R, Piras E, Orru S, Greco M, Carcassi C, Caocci G.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016048. eCollection 2016. Review.

27.

A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes.

Danjou F, Fozza C, Zoledziewska M, Mulas A, Corda G, Contini S, Dore F, Galleu A, Di Tucci AA, Caocci G, Gaviano E, Latte G, Gabbas A, Casula P, Delogu LG, La Nasa G, Angelucci E, Cucca F, Longinotti M.

Exp Hematol. 2016 Nov;44(11):1034-1038. doi: 10.1016/j.exphem.2016.07.005. Epub 2016 Jul 21.

PMID:
27449989
28.

Ruxolitinib therapy and telomere length in myelofibrosis.

Caocci G, Greco M, Delogu G, Secchi C, Perra A, Ghiani S, Orru F, Vacca A, Galimi F, La Nasa G.

Blood Cancer J. 2016 Oct 7;6(10):e479. doi: 10.1038/bcj.2016.91. No abstract available.

29.

Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors.

Caocci G, Vacca A, Piras E, Serreli V, Dessi C, Marcias M, Risso P, La Nasa G.

Bone Marrow Transplant. 2016 Dec;51(12):1640-1641. doi: 10.1038/bmt.2016.243. Epub 2016 Sep 19. No abstract available.

PMID:
27643871
30.

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.

Caocci G, Greco M, Delogu G, Secchi C, Martino B, Labate C, Abruzzese E, Trawinska MM, Galimberti S, Orru F, Fozza C, Gambacorti Passerini C, Galimi F, La Nasa G.

J Hematol Oncol. 2016 Jul 29;9(1):63. doi: 10.1186/s13045-016-0293-y.

31.

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.

Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG.

Am J Hematol. 2016 Oct;91(10):995-1001. doi: 10.1002/ajh.24463. Epub 2016 Jul 14.

32.

HLA-G expression and role in advanced-stage classical Hodgkin lymphoma.

Caocci G, Greco M, Fanni D, Senes G, Littera R, Lai S, Risso P, Carcassi C, Faa G, La Nasa G.

Eur J Histochem. 2016 Apr 11;60(2):2606. doi: 10.4081/ejh.2016.2606.

33.

Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis.

Caocci G, La Nasa G, Bain BJ.

Am J Hematol. 2016 Oct;91(10):1056. doi: 10.1002/ajh.24448. Epub 2016 Jul 4. No abstract available.

34.

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.

La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G.

J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4.

35.

Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis.

Littera R, Chessa L, Onali S, Figorilli F, Lai S, Secci L, La Nasa G, Caocci G, Arras M, Melis M, Cappellini S, Balestrieri C, Serra G, Conti M, Zolfino T, Casale M, Casu S, Pasetto MC, Barca L, Salustro C, Matta L, Scioscia R, Zamboni F, Faa G, Orrù S, Carcassi C.

PLoS One. 2016 Jan 8;11(1):e0146086. doi: 10.1371/journal.pone.0146086. eCollection 2016.

36.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.

Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.

Lancet Oncol. 2015 Nov;16(15):1506-1514. doi: 10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21.

PMID:
26404501
37.

Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?

Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F.

Crit Rev Oncol Hematol. 2015 Dec;96(3):542-54. doi: 10.1016/j.critrevonc.2015.07.012. Epub 2015 Aug 1. Review.

PMID:
26324461
38.

Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.

Caocci G, Maccioni A, Murgia F, Perra A, Usai M, Piga M, Mascia R, La Nasa G.

Leuk Lymphoma. 2016 May;57(5):1215-8. doi: 10.3109/10428194.2015.1079320. Epub 2015 Oct 5. No abstract available.

PMID:
26308187
39.

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.

Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, Ragatzu P, Galimberti S, Baratè C, Mulas O, Labate C, Littera R, Carcassi C, Gambacorti Passerini C, La Nasa G.

Exp Hematol. 2015 Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004. Epub 2015 Aug 22.

PMID:
26306453
40.

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F.

Leuk Res. 2015 Aug;39(8):859-65. doi: 10.1016/j.leukres.2015.05.012. Epub 2015 Jun 12.

PMID:
26120100
41.

T cell tyrosine phosphorylation response to transient redox stress.

Secchi C, Carta M, Crescio C, Spano A, Arras M, Caocci G, Galimi F, La Nasa G, Pippia P, Turrini F, Pantaleo A.

Cell Signal. 2015 Apr;27(4):777-88. doi: 10.1016/j.cellsig.2014.12.014. Epub 2015 Jan 6.

PMID:
25572700
42.

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.

Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F.

Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.

PMID:
25272332
43.

Leucocyte classification for leukaemia detection using image processing techniques.

Putzu L, Caocci G, Di Ruberto C.

Artif Intell Med. 2014 Nov;62(3):179-91. doi: 10.1016/j.artmed.2014.09.002. Epub 2014 Sep 16.

PMID:
25241903
44.

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report.

Caocci G, Greco M, La Nasa G.

J Med Case Rep. 2014 Sep 6;8:295. doi: 10.1186/1752-1947-8-295.

45.

Reassessing the approach to informed consent: the case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients.

Pisu S, Caocci G, d'Aloja E, Efficace F, Vacca A, Piras E, Orofino MG, Addari C, Pintor M, Demontis R, Demuru F, Pittau MR, Collins GS, La Nasa G.

Philos Ethics Humanit Med. 2014 Aug 12;9:13. doi: 10.1186/1747-5341-9-13.

46.

Immunological deregulation in classic hodgkin lymphoma.

Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G.

Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. Review.

47.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
48.

Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.

Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F.

Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557.

PMID:
24478321
49.
50.

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F.

Qual Life Res. 2014 Apr;23(3):825-36. doi: 10.1007/s11136-013-0523-5. Epub 2013 Sep 13.

PMID:
24026634

Supplemental Content

Loading ...
Support Center